Novavax (NASDAQ: NVAX) reported Q1 EPS of ($3.41), $0.01 better than the analyst estimate of ($3.42). Revenue for the quarter came in at $81 million versus the consensus estimate of $95.61 million.

GUIDANCE:

Novavax sees FY2023 revenue of $1400-1600 million, versus the consensus of $831.06 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.